Cancer immunotherapy

DBCAT005215Pharmacologic class

Drugs used for their immunological effects against cancer. A DrugBank category of 86 drugs. 85 of them are approved.

Part of: Immunotherapy
Also known as: anticancer immunotherapy · antineoplastic immunotherapy
Drugs: Aldesleukin
Alemtuzumab
Atezolizumab
Avelumab
Axicabtagene ciloleucel
BCG vaccine
Belantamab mafodotin
Belinostat
Bevacizumab
Blinatumomab
Brentuximab vedotin
Brexucabtagene autoleucel
Catumaxomab
Cemiplimab
Cetuximab
Daclizumab
Daratumumab
Denileukin diftitox
Denosumab
Dinutuximab
Durvalumab
Edrecolomab
Efalizumab
Elotuzumab
Enfortumab vedotin
and 61 more with a free account

What you can answer from here — as of January 08, 2021

86DrugsEach linked to its full drug card

88Drug targetsEvery drug–target pair in the class, with bond type

5,286Marketed productsAcross the regions we cover, with dosage forms and routes

22Routes of administrationHow the drugs in this class are given

Which targets do Cancer immunotherapy share, and which companies have late-stage candidates in this class?

Create a free account or log in to explore the full data card.